Cortical dysfunction in non-demented Parkinson's disease patients. A combined 31P-MRS and 18FDG-PET study

Brain

Volumn 123, Issue 2, 2000, Pages 340-352

  Hu, M T M ^b,d,e   Taylor Robinson, S D ^a,c   Chaudhuri, K Ray ^e   Bell, J D ^a   Labbe C ^b   Cunningham, V J ^b   Koepp, M J ^b,f   Hammers, A ^b   Morris, R G ^d   Turjanski, N ^b,d   Brooks, D J ^b,d,f  

^a Imaging sciences dept   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c Division of Medicine   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dementia; Glucose; Magnetic resonance spectroscopy; Parkinson's disease; PET

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN METABOLISM; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DEMENTIA; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; INTELLIGENCE TEST; LEARNING TEST; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033967662     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.2.340     Document Type: Article

References (63)

1. 14C]deoxyglucose labeling in optic tectum of the rattlesnake. J Neurophysiol 1983; 49: 1504-16.
2. Bailey DL. 3D acquisition and reconstruction in positron emission tomography. [Review]. Ann Nucl Med 1992; 6: 123-30.
3. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clarke JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996; 31: 1397-400.
4. Beck AT. Beck Depression Inventory. San Antonio (TX): The Psychological Corporation; 1978.
5. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. [Review]. Neurosci Biobehav Rev 1989; 13: 23-31.
6. Bottomley PA, Hart HR Jr, Edelstein WA, Schenck JF, Smith LS, Leue WM, et al. Anatomy and metabolism of the normal human brain studied by magnetic resonance at 1.5 Tesla. Radiology 1984; 150: 441-6.
7. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989; 39: 1423-7.
8. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984; 2: 1262-5.
9. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47: 454-65.
10. 31P MRS in vivo. Part I: cerebrum, cerebellum, cerebral gray and white matter. Magn Reson Med 1994; 32: 447-52.
11. Conn EE, Stumpf PK, Bruening G, Doi RH. Outlines of biochemistry. 5th edn. New York: John Wiley; 1987.
12. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114: 2095-122.
13. Coutts GA, Bryant DJ, Collins AG, Cox IJ, Sargentoni J, Gadian DG. 31P magnetic resonance spectroscopy of the normal human brain. Approaches using four dimensional chemical shift imaging and phase mapping techniques. NMR Biomed 1989; 1: 190-7.
14. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 15-23.
15. DeLong MR. Primate models of movement disorders of basal ganglia origin. [Review]. Trends Neurosci 1990; 13: 281-5.
16. DiMauro S. Mitochondrial involvement in Parkinson's disease: the controversy continues [editorial]. Neurology 1993; 43: 2170-2.
17. Eidelberg D, Moeeler JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990; 5: 203-13.
18. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14: 783-801.
19. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991; 11: 690-9.
20. Goto I, Taniwaki T, Hosokawa S, Otsuka M, Ichiya Y, Ichimiya A. Positron emission tomographic (PET) studies in dementia. J Neurol Sci 1993; 114: 1-6.
21. Hartigan JA. Clustering algorithms. New York: John Wiley; 1975.
22. Hope PL, Costello AM, Cady EB, Delpy DT, Tofts PS, Chu A, et al. Cerebral energy metabolism studied with phosphorus NMR spectroscopy in normal and birth-asphyxiated infants. Lancet 1984; 2: 366-70.
23. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Morris RG, Clough C, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999; 67: 20-6.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
25. 31P NMR spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 1985; 229: 141-51.
26. International Committee of Medical Journal Editors. Statements from the Vancouver Group. Br Med J 1991; 302: 1194.
27. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology 1997; 49: 764-73.
28. Koepp MJ, Hand KS, Labbé C, Richardson MP, Van Paesschen W, Baird VH, et al. In vivo [11C]flumazenil PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann Neurol 1998; 43: 618-26.
29. Kolb B, Whishaw IQ. Principles of cerebral asymmetry. In: Kolb B, Whishaw IQ. Fundamentals of human neuropsychology. 3rd edn. New York: W.H. Freeman; 1990. p. 347-82.
30. Labbé C, Koepp M, Ashburner J, Spinks T, Richardson M, Duncan J, et al. Absolute PET quantification with correction for partial volume effects within cerebral structures. In: Carson RE, Daube-Witherspoon ME, Herscovitch P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press; 1998. p. 59-66.
31. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106: 257-70.
32. Lenzi GL, Jones T, Reid JL, Moss S. Regional impairment of cerebral oxidative metabolism in Parkinson's disease. J Neurol Neurosurg Psychiatry 1979; 42: 59-62.
33. Levine SR, Helpern JA, Welch KM, Vande Linde AM, Sawaya KL, Brown EE, et al. Human focal cerebral ischemia: evaluation of brain pH and energy metabolism with P-31 NMR spectroscopy. Radiology 1992; 185: 537-44.
34. Mahieux F, Fenelon G, Flahault A, Manifacier M-J, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-83.
35. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492-7.
36. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. [Review]. Neurology 1996; 47: 1113-24.
37. McLaughlin BA, Nelson D, Erecinska M, Chesselet MF. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J Neurochem 1998; 70: 2406-15.
38. Minoshima S, Foster NL, Frey KA, Wahl RL, Burdette JH, Kuhl DE. Can FDG PET distinguish dementia patients with cortical Lewy bodies from pure Alzheimer's disease? [abstract]. J Nucl Med 1997; 38 (5 Suppl): 70P-71P.
39. Morikawa N, Nakagawa-Hattori Y, Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J Neurochem 1996; 66: 1174-81.
40. Murphy DG, Bottomley PA, Salerno JA, DeCarli C, Mentis MJ, Grady CL, et al. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 1993; 50: 341-9.
41. Nelson HE. National Adult Reading Test (NART) 2nd edn. Oxford: NFER-Nelson; 1991.
42. 31P NMR. J Appl Physiol 1987; 62: 2094-102.
43. Paolo AM, Troster AI, Ryan JJ. California Verbal Learning Test: normative data for the elderly. J Clin Exp Neuropsychol 1997; 19: 220-34.
44. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49: 1262-8.
45. 31P nuelear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol 1988; 47: 235-18.
46. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med 1996; 37: 1115-22.
47. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992; 32: 151-61.
48. Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, et al. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/ photomultiplier assembly and non-stick tubing. Med Prog Technol 1991; 17: 259-64.
49. Saeed N. A knowledge-based approach to deconvolve the water component in in vivo proton MR spectroscopy. J Comput Assist Tomogr 1995; 19: 830-7.
50. Sagar HJ. Psychopharmacology of cognitive impairment in Parkinson's disease. In: Perry R, McKeith I, Perry E, editors. Dementia with Lewy body. Clinical, pathological and treatment issues. Cambridge: Cambridge University Press. 1996; p. 363-79.
51. Schapira AH, Mann VM, Cooper JM, Krige D, Jenner PJ, Marsden CD. Mitochondrial function in Parkinson's disease. [Review]. Ann Neurol 1992; 32 Suppl: S116-24.
52. Siegel GJ, Agranoff BW, Albers RW, Molinoff P. Basic neurochemistry: molecular, cellular and medical aspects. 4th ed. New York: Raven Press: 1989.
53. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. [Review]. J Neurochem 1977; 29: 13-26.
54. Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootoonk S, Bloomfield PM, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992; 37: 1637-55.
55. Spreen O, Strauss E. Controlled oral word association (word fluency). In: Spreen O, Strauss E. A compendium of neuropsychological tests. Administration, norms and commentary. Oxford: Oxford University Press; 1991. p. 219-27.
56. Taylor-Robinson SD, Buckley C, Changani KK, Hodgson HJ, Bell JD. Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. Liver. In press 1999.
57. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alperovitch A. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45: 705-8.
58. Tsuji M, Allred E, Jensen F, Holtzman D. Phosphocreatine and ATP regulation in the hypoxic developing rat brain. Brain Res Dev Brain Res 1995; 85: 192-200.
59. Van Gorp WG, Satz P, Kiersche ME, Henry R. Normative data on the Boston Naming Test for a group of normal older adults. J Clin Exp Neuropsychol 1986; 8: 702-5.
60. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38: 797-802.
61. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? [editorial]. [Review]. J Neurol 1994; 241: 354-71.
62. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993; 17: 536-46.
63. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.